Vaxcyte Shares Surge on Pneumococcal Vaccine Trial Success
Vaxcyte announced its experimental pneumococcal vaccine achieved its primary endpoints in a late-stage trial for adults aged 50 and older, causing its shares to jump 91% pre-market.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.